The document provides information about the 14th Annual Conference on Pain Therapeutics to be held on May 19-20, 2014 in London. It summarizes that attendees can register by February 28th to receive a £300 discount or by March 31st to receive a £100 discount. The conference will discuss assessing alternative approaches to animal models to minimize the translational gap and accelerate market access. It will feature key speakers from companies such as Merck, Eli Lilly, and AbbVie discussing advances in pain therapeutics from bench to bedside. The conference will also explore topics such as neuropathic pain, opioids, and strategies to reduce abuse potential. Two post-conference workshops on May 21st will focus on improving success in
This document provides information about the 18th annual Pain Therapeutics conference taking place May 21-23, 2018 in London. The conference and two post-conference workshops will explore innovative approaches and novel targets for analgesic medicine. Featured speakers will discuss topics like DNA-based treatments for neuropathic pain, targeting ion channels to reduce pain, and clinical trials in chronic pain. Attendees can learn about drug development challenges and potential solutions for issues like patient recruitment and placebo responses.
Innovation in Phase 1 Clinical DevelopmentElisa_Ramella
Practical app roaches to
phase I trial develop ment
to enable faster go / no -go
decision s, reduce co st and
speed time to market
www.phase1clinicaldevelopment.com
This document discusses ion channels and voltage-gated sodium channels. It describes the molecular architecture of ion channels, including that they consist of subunits containing transmembrane helices and pore loops. It also discusses the different types of ion channels, including voltage-gated, ligand-gated, and mechanically-gated channels. Finally, it provides details on voltage-gated sodium channels, their role in action potentials, classification, gene mutations, and common blockers like tetrodotoxin.
Trauma or injury causes the release of chemicals that stimulate nerve fibers, leading to pain signals being sent to the brain. The integration of these pain signals with cognitive, emotional, and environmental factors results in the perception of pain. When this balance is disturbed, chronic pain can develop. Chronic pain is defined as pain lasting beyond normal tissue healing time, typically three months. A multidisciplinary approach is often needed to treat chronic pain through non-pharmacological and pharmacological methods.
This document discusses neuropathic pain, its causes, symptoms, and treatment options. It begins by defining neuropathic pain as pain resulting from damage or disease affecting the somatosensory nervous system, such as diabetic neuropathy or postherpetic neuralgia. Symptoms include abnormal sensations like tingling, burning, and pain from stimuli that are normally non-painful. Treatment options discussed include tricyclic antidepressants, gabapentin, pregabalin, serotonin-norepinephrine reuptake inhibitors, topical lidocaine, opioids, and emerging treatments like botulinum toxin, cannabinoids, spinal cord stimulation, and intrathecal drug delivery.
The document discusses neuropathic pain and its treatment. It defines neuropathic pain as pain initiated or caused by primary lesions or dysfunction in the nervous system. Some examples of neuropathic pain given are postherpetic neuralgia, diabetic peripheral neuropathy, and post-surgical neuropathy. The document outlines approaches to diagnosing neuropathic pain, including listening to the patient's description of their pain, looking for sensory abnormalities, and locating the region of pain to a neuroanatomical area. It discusses treating neuropathic pain with topical medications, systemic medications like anticonvulsants, antidepressants and opioids.
This document provides information about the 18th annual Pain Therapeutics conference taking place May 21-23, 2018 in London. The conference and two post-conference workshops will explore innovative approaches and novel targets for analgesic medicine. Featured speakers will discuss topics like DNA-based treatments for neuropathic pain, targeting ion channels to reduce pain, and clinical trials in chronic pain. Attendees can learn about drug development challenges and potential solutions for issues like patient recruitment and placebo responses.
Innovation in Phase 1 Clinical DevelopmentElisa_Ramella
Practical app roaches to
phase I trial develop ment
to enable faster go / no -go
decision s, reduce co st and
speed time to market
www.phase1clinicaldevelopment.com
This document discusses ion channels and voltage-gated sodium channels. It describes the molecular architecture of ion channels, including that they consist of subunits containing transmembrane helices and pore loops. It also discusses the different types of ion channels, including voltage-gated, ligand-gated, and mechanically-gated channels. Finally, it provides details on voltage-gated sodium channels, their role in action potentials, classification, gene mutations, and common blockers like tetrodotoxin.
Trauma or injury causes the release of chemicals that stimulate nerve fibers, leading to pain signals being sent to the brain. The integration of these pain signals with cognitive, emotional, and environmental factors results in the perception of pain. When this balance is disturbed, chronic pain can develop. Chronic pain is defined as pain lasting beyond normal tissue healing time, typically three months. A multidisciplinary approach is often needed to treat chronic pain through non-pharmacological and pharmacological methods.
This document discusses neuropathic pain, its causes, symptoms, and treatment options. It begins by defining neuropathic pain as pain resulting from damage or disease affecting the somatosensory nervous system, such as diabetic neuropathy or postherpetic neuralgia. Symptoms include abnormal sensations like tingling, burning, and pain from stimuli that are normally non-painful. Treatment options discussed include tricyclic antidepressants, gabapentin, pregabalin, serotonin-norepinephrine reuptake inhibitors, topical lidocaine, opioids, and emerging treatments like botulinum toxin, cannabinoids, spinal cord stimulation, and intrathecal drug delivery.
The document discusses neuropathic pain and its treatment. It defines neuropathic pain as pain initiated or caused by primary lesions or dysfunction in the nervous system. Some examples of neuropathic pain given are postherpetic neuralgia, diabetic peripheral neuropathy, and post-surgical neuropathy. The document outlines approaches to diagnosing neuropathic pain, including listening to the patient's description of their pain, looking for sensory abnormalities, and locating the region of pain to a neuroanatomical area. It discusses treating neuropathic pain with topical medications, systemic medications like anticonvulsants, antidepressants and opioids.
this presentation discusses pain pathways, definition and glossary of pain symptoms, classification of pain, pathogenesis, causes, diagnosis , types and treatment of neuropathic pain
illustrated with figures
This document discusses ion channels, which are pore-forming membrane proteins that control the flow of ions across cell membranes. There are two main classes of ion channels: voltage-gated channels, whose gating is controlled by membrane polarization, and ligand-gated channels, whose gating is controlled by the binding of intracellular ligands. The document provides examples of different types of ion channels including potassium channels, calcium channels, chloride channels, GABA and glycine receptors. It also discusses some drugs that work by blocking specific ion channels and their potential applications.
This document provides information on neuropathic pain diagnosis and management, with a focus on diabetic peripheral neuropathy. It discusses:
- The different types of pain (nociceptive, neuropathic, central sensitization) and characteristics of each. Neuropathic pain is caused by damage to the somatosensory nervous system and is often chronic.
- Neuropathic pain is prevalent in many conditions including diabetes, cancer, HIV, post-surgical, and postherpetic neuralgia. Over 50% of people with diabetes experience painful diabetic peripheral neuropathy.
- The pathophysiology of neuropathic pain involves peripheral and central nervous system changes that lead to hypersensitivity and abnormal pain response. Sleep disruption and anxiety/depression can
The document discusses neuropathic pain, including its pathophysiology, symptoms, causes, assessment, and treatment approaches. It provides details on pharmacological and non-pharmacological treatment options for peripheral and central neuropathic pain, including guidelines on first-line therapies such as antidepressants, anticonvulsants, and topical lidocaine. Emerging treatments currently under investigation are also mentioned.
1. The document discusses pain, defining it as an unpleasant sensory and emotional experience associated with actual or potential tissue damage.
2. Pain is always subjective and can be somatic, visceral, or neuropathic in nature. It can be acute or chronic, with chronic pain lasting over 3 months and having a large psycho-social component.
3. The gate control theory proposes that psychological factors can affect the experience of pain by opening and closing a "gate" in the spinal cord that modulates pain transmission.
Ion channels, types and their importace in managment of diseasesFarazaJaved
This topic covers voltage gated type of ion channel, general structure and functioning of ion channels and involvement of different ion channel types in the pathogenesis as wella as a target for the development of various diseases.
This document provides an overview of pain, including definitions, classifications, physiology, assessment, and management. It defines pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Pain is classified based on location, duration (acute vs chronic), and intensity (mild, moderate, severe). The physiology of pain involves transduction, transmission, modulation, and perception of pain signals in the nervous system. Nurses assess pain using scales and treat it using pharmacological and non-pharmacological methods based on the type and severity of the pain.
This document provides information about an upcoming conference on pain therapeutics taking place from May 22-24, 2017 in London. It summarizes the conference agenda, speakers, and topics to be discussed over the two day event and half day workshop. Key highlights include:
- The conference will focus on strategies for pain management, evaluating translation between pre-clinical and clinical studies, assessing animal models for studying pain pathways, and examining new case studies from pharmaceutical companies.
- Speakers will address topics like CGRP receptor antagonists for migraine, developing novel pain treatments, using veterinary trials to inform human research, biomarkers for pain pathways, and new therapeutic approaches for pain including Kappa opioid receptor agonists.
-
The document announces a half-day post-conference workshop on innovation in analgesic drug development taking place on May 15, 2019 in London. The workshop will feature highlights including exploring advances in migraine therapy with Eli Lilly and Reckitt Benckiser, overcoming challenges in developing treatments for chemotherapy-induced peripheral neuropathy, and engaging in discussions on novel treatment methodologies and public-private partnerships for drug development. The workshop aims to address accelerating clinical development to help address the opioid crisis and will review over 100 analgesic compounds in development pipelines.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
The Clinical Trial in Oncology event on 1-2 December 2009 in Munich will show you how to utilise target approaches to optimize your clinical research and enhance your patient enrolment, data quality and much more.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
Interviews with Dr Torsten Hoffmann (Summit Chairman), Dr Bertil Lindmark and Herbie Newell, speakers at the marcus evans Discovery Summit 2014, taking place in Lisbon, Portugal, 31 March - 1 April 2014.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.
This document provides an overview and agenda for the 2nd annual conference on drug discovery taking place on March 21st-22nd, 2018 in London. The conference will feature presentations and discussions on:
1) New technologies to improve discovery cycles in chemistry and drug discovery processes, including the role of artificial intelligence and new modalities like PROTACs and antibodies.
2) Advances in small molecule therapeutics from Roche and challenges in validating targets with CRISPR from Epizyme.
3) The role of open access chemical probes from the SGC and how Bayer uses them in drug discovery.
4) How artificial intelligence can transform drug design and discovery efforts at companies like Exscient
SMi Group's 9th annual Pre-filled Syringes Europe 2017 Dale Butler
This document provides information on two half-day pre-conference workshops on January 17th, 2017 regarding pre-filled syringes in London, UK. Workshop A from 8:30-12:30 will explore how personalized medicine, enhanced patient experience, and improved outcomes will drive the development of digital therapy management ecosystems and how this will impact future parenteral drug delivery devices. Workshop B from 13:30-18:15 will examine regulatory challenges at the interface of medicines and medical devices. Both workshops aim to provide insights on these important topics for professionals in the pre-filled syringes industry.
This document is a curriculum vitae for Chris van Groeningen, a clinical researcher. It summarizes his experience including positions at various medical device companies where he conducted clinical research and product development. It also lists his education including a PhD in human physics and masters in biology. He has 5 US patents and publications in medical journals. In his free time, he volunteers as a chef for organizations providing meals to the homeless.
SMi Group's Superbugs and Superdrugs USA 2016Dale Butler
This document provides information about the "Superbugs & Superdrugs USA" conference happening from November 14-16, 2016. It advertises the opportunity to register for the conference at discounted rates by certain deadlines. The conference will focus on developing new drugs to combat antibiotic resistance and will feature expert speakers from organizations like the WHO, BARDA, NIH, Pfizer and others. An interactive workshop on animal models in pre-clinical drug development will also be held.
This document summarizes a two-day conference on pain therapeutics held on May 20-21, 2013 in London. The conference featured speakers from major pharmaceutical companies and universities discussing topics related to pain treatment including personalized medicine, novel drug targets, clinical trial models, and overcoming challenges. An interactive post-conference workshop on May 22nd focused on improving human pain models and their translation to clinical practice.
this presentation discusses pain pathways, definition and glossary of pain symptoms, classification of pain, pathogenesis, causes, diagnosis , types and treatment of neuropathic pain
illustrated with figures
This document discusses ion channels, which are pore-forming membrane proteins that control the flow of ions across cell membranes. There are two main classes of ion channels: voltage-gated channels, whose gating is controlled by membrane polarization, and ligand-gated channels, whose gating is controlled by the binding of intracellular ligands. The document provides examples of different types of ion channels including potassium channels, calcium channels, chloride channels, GABA and glycine receptors. It also discusses some drugs that work by blocking specific ion channels and their potential applications.
This document provides information on neuropathic pain diagnosis and management, with a focus on diabetic peripheral neuropathy. It discusses:
- The different types of pain (nociceptive, neuropathic, central sensitization) and characteristics of each. Neuropathic pain is caused by damage to the somatosensory nervous system and is often chronic.
- Neuropathic pain is prevalent in many conditions including diabetes, cancer, HIV, post-surgical, and postherpetic neuralgia. Over 50% of people with diabetes experience painful diabetic peripheral neuropathy.
- The pathophysiology of neuropathic pain involves peripheral and central nervous system changes that lead to hypersensitivity and abnormal pain response. Sleep disruption and anxiety/depression can
The document discusses neuropathic pain, including its pathophysiology, symptoms, causes, assessment, and treatment approaches. It provides details on pharmacological and non-pharmacological treatment options for peripheral and central neuropathic pain, including guidelines on first-line therapies such as antidepressants, anticonvulsants, and topical lidocaine. Emerging treatments currently under investigation are also mentioned.
1. The document discusses pain, defining it as an unpleasant sensory and emotional experience associated with actual or potential tissue damage.
2. Pain is always subjective and can be somatic, visceral, or neuropathic in nature. It can be acute or chronic, with chronic pain lasting over 3 months and having a large psycho-social component.
3. The gate control theory proposes that psychological factors can affect the experience of pain by opening and closing a "gate" in the spinal cord that modulates pain transmission.
Ion channels, types and their importace in managment of diseasesFarazaJaved
This topic covers voltage gated type of ion channel, general structure and functioning of ion channels and involvement of different ion channel types in the pathogenesis as wella as a target for the development of various diseases.
This document provides an overview of pain, including definitions, classifications, physiology, assessment, and management. It defines pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Pain is classified based on location, duration (acute vs chronic), and intensity (mild, moderate, severe). The physiology of pain involves transduction, transmission, modulation, and perception of pain signals in the nervous system. Nurses assess pain using scales and treat it using pharmacological and non-pharmacological methods based on the type and severity of the pain.
This document provides information about an upcoming conference on pain therapeutics taking place from May 22-24, 2017 in London. It summarizes the conference agenda, speakers, and topics to be discussed over the two day event and half day workshop. Key highlights include:
- The conference will focus on strategies for pain management, evaluating translation between pre-clinical and clinical studies, assessing animal models for studying pain pathways, and examining new case studies from pharmaceutical companies.
- Speakers will address topics like CGRP receptor antagonists for migraine, developing novel pain treatments, using veterinary trials to inform human research, biomarkers for pain pathways, and new therapeutic approaches for pain including Kappa opioid receptor agonists.
-
The document announces a half-day post-conference workshop on innovation in analgesic drug development taking place on May 15, 2019 in London. The workshop will feature highlights including exploring advances in migraine therapy with Eli Lilly and Reckitt Benckiser, overcoming challenges in developing treatments for chemotherapy-induced peripheral neuropathy, and engaging in discussions on novel treatment methodologies and public-private partnerships for drug development. The workshop aims to address accelerating clinical development to help address the opioid crisis and will review over 100 analgesic compounds in development pipelines.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
The Clinical Trial in Oncology event on 1-2 December 2009 in Munich will show you how to utilise target approaches to optimize your clinical research and enhance your patient enrolment, data quality and much more.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
Interviews with Dr Torsten Hoffmann (Summit Chairman), Dr Bertil Lindmark and Herbie Newell, speakers at the marcus evans Discovery Summit 2014, taking place in Lisbon, Portugal, 31 March - 1 April 2014.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.
This document provides an overview and agenda for the 2nd annual conference on drug discovery taking place on March 21st-22nd, 2018 in London. The conference will feature presentations and discussions on:
1) New technologies to improve discovery cycles in chemistry and drug discovery processes, including the role of artificial intelligence and new modalities like PROTACs and antibodies.
2) Advances in small molecule therapeutics from Roche and challenges in validating targets with CRISPR from Epizyme.
3) The role of open access chemical probes from the SGC and how Bayer uses them in drug discovery.
4) How artificial intelligence can transform drug design and discovery efforts at companies like Exscient
SMi Group's 9th annual Pre-filled Syringes Europe 2017 Dale Butler
This document provides information on two half-day pre-conference workshops on January 17th, 2017 regarding pre-filled syringes in London, UK. Workshop A from 8:30-12:30 will explore how personalized medicine, enhanced patient experience, and improved outcomes will drive the development of digital therapy management ecosystems and how this will impact future parenteral drug delivery devices. Workshop B from 13:30-18:15 will examine regulatory challenges at the interface of medicines and medical devices. Both workshops aim to provide insights on these important topics for professionals in the pre-filled syringes industry.
This document is a curriculum vitae for Chris van Groeningen, a clinical researcher. It summarizes his experience including positions at various medical device companies where he conducted clinical research and product development. It also lists his education including a PhD in human physics and masters in biology. He has 5 US patents and publications in medical journals. In his free time, he volunteers as a chef for organizations providing meals to the homeless.
SMi Group's Superbugs and Superdrugs USA 2016Dale Butler
This document provides information about the "Superbugs & Superdrugs USA" conference happening from November 14-16, 2016. It advertises the opportunity to register for the conference at discounted rates by certain deadlines. The conference will focus on developing new drugs to combat antibiotic resistance and will feature expert speakers from organizations like the WHO, BARDA, NIH, Pfizer and others. An interactive workshop on animal models in pre-clinical drug development will also be held.
This document summarizes a two-day conference on pain therapeutics held on May 20-21, 2013 in London. The conference featured speakers from major pharmaceutical companies and universities discussing topics related to pain treatment including personalized medicine, novel drug targets, clinical trial models, and overcoming challenges. An interactive post-conference workshop on May 22nd focused on improving human pain models and their translation to clinical practice.
This document summarizes a two-day conference on pain therapeutics taking place on May 20-21, 2013 in London. The conference will feature speakers from major pharmaceutical companies discussing topics like personalized medicine in pain treatment, novel drug targets, anti-NGF therapies, and optimizing treatments for arthritis pain. Attendees will include researchers and scientists working on pain and inflammation. The agenda also includes workshops on improving human pain models and using imaging to enhance early drug development.
This document provides information about the 10th Annual Conference on RNA Therapeutics taking place on February 20-21, 2019 in London. It outlines the chairs, guest speakers, and key speakers at the conference, as well as featured highlights and topics to be discussed. Some of the topics to be covered include the clinical progress of spherical nucleic acids with Exicure, Sanofi's strategies for oligonucleotide delivery, ProQR's plans for oligonucleotide supply, and the development of self-amplifying mRNA vaccines at GSK. The document provides an agenda and schedule for the two-day conference.
2nd Annual Oncology Asia
Date: 7 – 9 September 2015 | Sheraton Miyako, Tokyo, Japan
www.oncologyasia.com
The 2nd Annual Oncology Asia zeroes in on the latest cutting edge developments in oncology drug discovery and late phase strategies to get oncology drugs to market faster! Under the Drug Discovery track, this conference will discuss latest immune checkpoint inhibitor combinations, preclinical development trends, novel biomarkers and oncology drug development case studies in Asia. Under the late phase track, it will discuss pricing for success, global and regional commercialization case studies, healthcare policy updates and pricing for success.
Find out about the latest drug discovery trends along with latest strategies for global and regional commercialization at the ONLY senior industry gathering focused on advancing cutting edge oncology R&D and commercialization strategies for Asia in Tokyo, Japan!
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
Accelerating the translation of medical research - 27 JuneInnovation Agency
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
Med Knowledge Imp to Sales Team - Role of Med. Aff. Speaker Dr. KK 2023 10 03...AmeetRathod3
This document provides an overview of the importance of medical knowledge for sales and marketing teams in the pharmaceutical industry. It discusses how understanding medical terminology, disease states, and clinical data enhances sales representatives' scientific competency and ability to have effective discussions with physicians. The document also outlines the roles of the medical affairs department in providing training to sales teams on therapy areas, products, clinical trials, and addressing medical queries to improve their knowledge. It emphasizes that physicians prefer engaging with representatives who demonstrate strong clinical and scientific expertise.
Similar to SMi Group's 14th annual Pain Therapeutics conference (20)
SMi Group's Pharmaceutical Microbiology West Coast 2020 conferenceDale Butler
This document provides information on the Pharmaceutical Microbiology West Coast conference happening June 17-19, 2020 in San Diego. It outlines the chairs, speakers, highlights and agenda for the event. The conference will focus on novel approaches and best practices for tackling current industry contamination control challenges, and will include sessions on contamination control, guidance and regulations, detection and identification methods, and supporting pharmaceutical facilities and novel therapeutics. There will also be an optional pre-conference workshop on data integrity in environmental monitoring.
SMi Group's Pre-filled Syringes West Coast 2020 conferenceDale Butler
This document provides an agenda for the 5th annual Pre-Filled Syringes West Coast conference taking place June 15-17, 2020 in San Diego, CA. The conference will focus on innovations in device design and technology, advances in human factors engineering, combination product regulatory insights, and design controls and risk management. It will feature presentations from industry leaders at companies like Genentech and AstraZeneca as well as regulators from the FDA. There will also be two post-conference workshops on June 17th focusing on navigating FDA requirements for connected devices and digital health, and post-market safety reporting for combination products.
SMi Group's Military Robotics and Autonomous Systems USA 2020 conferenceDale Butler
This document advertises the Military Robotics and Autonomous Systems USA conference happening on June 22-23, 2020 in Arlington, Virginia. Attendees can save $400 by registering by February 28, $200 by registering by March 31, and $100 by registering by April 30. The conference will discuss topics like US Army robotics programs, Australian Army robotics development, unmanned vehicle programs, robotics supporting warfighters' mobility and sustainability, and integrating robotics into ground formations. Speakers will include representatives from the US and Australian militaries as well as academics working on relevant research.
SMi Group's Future Soldier Technology USA 2020 conferenceDale Butler
The document announces the 2nd Annual Future Soldier Technology USA conference on June 8-10, 2020 in Arlington, Virginia. The conference will focus on modernizing equipment for dismounted soldiers and marines, and feature speakers from the US and other militaries involved in soldier technology programs. Over 150 attendees are expected to discuss initiatives like NGSW-AR/R/FC, ISSP, and manned-unmanned teaming to enhance soldier lethality, mobility, and situational awareness.
SMi Group's Military Space USA 2020 conferenceDale Butler
This document provides an agenda for the 2nd Annual Military Space USA Conference supporting the US military space enterprise. The conference will include presentations from senior leaders in the US Space Force, Air Force, and other allied militaries on topics such as space acquisition reform through SMC 2.0, training the future space warfighting force, and leveraging disruptive commercial space technologies. A separate focus day will explore experimental smallsat capabilities, export controls for space technologies, advanced propulsion concepts, using LEO mega-constellations for bandwidth, in-orbit manufacturing, and accelerating commercial innovation. The event aims to connect disruptors and innovators with government to integrate new technologies rapidly into military space operations.
This document summarizes a conference focused on helicopter technology for Central and Eastern Europe being held in Budapest, Hungary on May 20-21, 2020. It will feature keynote speeches from military leaders from Hungary, Slovakia, Romania, Germany, and Croatia on developments and modernization efforts of their national helicopter fleets. Technical experts from the US, UK, Netherlands, and Czech Republic will also present. Sessions will discuss regional cooperation and interoperability, training standards, and enhancing capabilities like search and rescue. The goal is focused discussion on challenges facing helicopter program managers and informal networking for participants.
This document provides information about an upcoming conference on future armoured vehicles in Central and Eastern Europe in 2020. It outlines early registration discounts that decrease over time, as well as special rates for military and government representatives. The document details benefits of attending the conference, including hearing updates from armed forces in the region. It lists speakers from various countries who will discuss topics like armoured vehicle programmes, enhancing capabilities, and ensuring interoperability. The agenda outlines presentations over two days covering issues like future infantry fighting vehicles, enhancing mechanization capabilities, and modernizing ground platforms. The document promotes sponsorship opportunities at the event.
SMi Group's Unmanned Maritime Systems 2020 conferenceDale Butler
This document provides information about the 4th Annual Unmanned Maritime Systems conference taking place on April 13-14, 2020 in London. It discusses key reasons to attend like hearing from naval officers on integrating unmanned assets and learning about updates on unmanned platforms, anti-submarine warfare, mine countermeasures, and technological innovation. The agenda outlines presentations and speakers from military organizations like the Royal Navy, US Navy, Spanish Navy, and NATO who will discuss topics like developing unmanned systems, accelerating unmanned technologies, and using unmanned systems for mine countermeasure operations.
SMi Group's Military PNT 2020 conferenceDale Butler
The document summarizes the agenda for the "Military PNT 2020" conference to be held on May 18-19 in London. The event highlights include briefings from the US DoD on GPS and NTS-3 programs, understanding requirements for operating in degraded PNT environments, and engaging with industry and military leaders. The agenda covers topics such as UK PNT strategies, warfighter PNT considerations, legal perspectives on PNT resilience, and GNSS interference case studies. Keynote speakers include representatives from the US Air Force, Lockheed Martin, UK MoD, DGA, NPL, and BHO Legal.
This document provides an agenda for the Defence Aviation Safety conference taking place on April 23-24, 2020 in London. The agenda includes keynote presentations and panels on topics related to ensuring safety across defence aviation programs and platforms. Speakers will represent organisations such as the UK Ministry of Defence, US Air Force, German Military Aviation Authority, and NATO. Presentation topics will cover safety priorities, certification processes, training, accident investigation and lessons learned. A closing panel on day two will discuss the challenges of ensuring military aviation safety and cyber resilience.
SMi Group's Pre-filled Syringes East Coast 2020 Dale Butler
This document announces an interactive workshop on combination product development taking place on April 29th, 2020 in Boston, USA. The workshop will consist of three sessions focused on key topics in combination product development: combination product development strategies, drug delivery device testing solutions, and human factors validation studies. Speakers will include experts from major pharmaceutical companies such as AstraZeneca, Eli Lilly, Biogen, and regulatory agencies. The workshop aims to provide attendees insights and strategies for navigating challenges in combination product development from concept to approval.
SMi Group's Air Mission Planning and Support 2020Dale Butler
The document announces an upcoming conference on "Maximising Air Power through the Development and Integration of Innovative Support Systems" to be held in London on April 21-22, 2020. The conference will examine developments in air mission planning and focus on data management, fifth generation integration, and multi-domain command and control. It will feature expert military speakers from countries like the UK, US, Canada, France, Hungary, and Belgium representing air forces, NATO, and DARPA to discuss challenges and solutions.
SMi Group's Military Robotics and Autonomous Systems 2020 Dale Butler
This document provides information about the 3rd Annual Military Robotics and Autonomous Systems conference taking place on April 1-2, 2020 in London. It outlines the key topics to be discussed including UK and international perspectives on robotic and autonomous systems programs and strategies. Speakers will address topics such as unmanned ground vehicle development, autonomy for military robotic systems, and manned-unmanned teaming. The conference will explore delivering quality robotic systems to enhance operational effectiveness and discuss technology demonstrations.
This document advertises the 6th Annual Future Soldier Technology conference taking place March 9-11, 2020 in London. The conference will focus on dismounted soldier and marine technology, discussing key areas like dismounted capability. Military, procurement, and research experts from around the world will present on their soldier programs, challenges, and successes. Attendees can learn the latest developments, network with key speakers and decision makers, and gather intelligence to inform their projects. The conference aims to allow information sharing on equipping soldiers to maintain an advantage against evolving adversaries.
This document provides information about the 5th Annual Defence Logistics Central & Eastern Europe conference taking place on March 3-4, 2020 in Budapest, Hungary. The summary includes:
- The conference will bring together senior military, government, and industry personnel from Central and Eastern Europe to discuss developments in defence logistics and increase cooperation in the region.
- Over the two days, there will be keynote briefings and panels on topics like modernizing logistics structures, interoperability, operational capabilities of country logistics divisions, and industry roles. Speakers will represent militaries like Hungary, Czech Republic, Poland, and industry sponsors.
- Attendees can benefit from networking opportunities and learning about log
The document announces Space Week, consisting of the Small Satellites Conference from April 27-28 and the Military Space Situational Awareness Conference from April 29-30 in London. It provides details on the conferences, including chairpersons, speakers from various space agencies, companies, and militaries, and topics to be discussed such as small satellites, space insurance, disruptive approaches to space, space data, and military space situational awareness. The document aims to invite colleagues to participate in Space Week to explore developments in small satellites and how to track and manage space assets.
SMi Group's Superbugs and Superdrugs 2020 conferenceDale Butler
This document provides information about the Superbugs & Superdrugs conference on March 30-31, 2020 in London. The conference will focus on non-traditional approaches to fighting antimicrobial resistance and will feature speakers from companies and organizations working on alternatives to antibiotics, including those developing antibacterial proteins, agents that neutralize bacterial virulence, direct lytic agents, and immunomodulatory therapies. It provides details on the agenda, speakers, workshops, registration and sponsorship opportunities.
SMi Group's AI in Drug Discovery 2020 conferenceDale Butler
This document provides information about an upcoming conference on AI in Drug Discovery taking place from March 16-17, 2020 in London, UK. It includes details about the program, speakers, registration fees and deadlines. The conference will explore how machine learning and AI are being applied across the drug discovery process, from compound design and virtual screening to toxicity prediction. There will be case studies presented from major pharmaceutical companies on their experience integrating AI. The document also advertises sponsorship opportunities for the event.
Nutritional deficiency Disorder are problems in india.
It is very important to learn about Indian child's nutritional parameters as well the Disease related to alteration in their Nutrition.
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Jim Jacob Roy
In this presentation , SBP ( spontaneous bacterial peritonitis ) , which is a common complication in patients with cirrhosis and ascites is described in detail.
The reference for this presentation is Sleisenger and Fordtran's Gastrointestinal and Liver Disease Textbook ( 11th edition ).
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...Donc Test
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
1. REGISTER BY 28TH FEBRUARY AND RECEIVE A £300 DISCOUNT
REGISTER BY 31ST MARCH AND RECEIVE A £100 DISCOUNT
SMi present the 14th Annual Conference on…
PAIN THERAPEUTICS
Assess Alternative Approaches to Animal Models to Minimise
the Translational Gap and Accelerate Market Access
19TH - 20TH
MAY
2014
Holiday Inn Regents Park Hotel, London, UK
CONFERENCE CHAIRS FOR 2014:
• Jordi Serra, Chief Scientific
Officer, Neuroscience
Technologies Ltd
• Dr Kathleen Kelly, Medical
Leader, Janssen
Pharmaceutical Research
& Development L.L.C.
KEY SPEAKERS INCLUDE:
• Samer Eid, Director,
Neuroscience Scientific
Knowledge Discovery,
Merck
• Tom McCarthy, CEO,
Spinifex
• Zara Sands, Principal
Scientist, Computational
Medicinal Chemist, UCB
• Birgit Priest, Research
Advisor, Eli Lilly
• Philip R Kym, Director of
Chemistry, Centralised Lead,
Optimisation, AbbVie
• Stephen Wright, R&D
Director, GW
Pharmaceuticals
BUSINESS BENEFITS FOR 2014:
• Discuss and evaluate the latest new therapeutic mechanisms
from bench to bedside with key insight from Merck, Spinifiex, Eli
Lilly, AbbVie and UCB
• Hear key presentations from Mundipharma Research and Nektar
on advances to opioids and strategies to reduce abuse potential
• Explore the latest in the area of Neuropathic pain for 2014 with
the latest case studies from Neuroscience Technologies and GW
Pharmaceuticals
• Evaluate the translation gap with case studies from a pre-clinical
and clinical perspective from Karolinska Institutet and
OGBConsulting
PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS
Wednesday 21st May 2014, Holiday Inn Regents Park Hotel, London, UK
A: How Can Success in Analgesia be Improved?
B: Opportunities for Collaborative Pain Projects
Workshop Leaders: Steve Harrison, Vice President, Research Biology,
Nektar Pharmaceuticals
Birgit Priest, Research Advisor, Eli Lilly
8.30am - 12.30pm
Workshop Leader: Fiona Boissonade, Head of Neuroscience,
University of Sheffield
1.30pm - 5.30pm
www.pain-therapeutics.co.uk
BOOK BY 28TH FEBRUARY AND SAVE £300 / BOOK BY 31ST MARCH AND SAVE £100
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
2. Pain Therapeutics
www.pain-ther
Day One | Monday 19th May 2014
8.30
Registration & Coffee
12.50
Networking Lunch
9.00
Chairman's Opening Remarks
Dr Kathleen Kelly, Medical Leader, Janssen Pharmaceutical
Research & Development L.L.C.
1.50
How do we produce a step change in the discovery of new
analgesics?
• Epigenetic proteins are fundamental mediators of chronic
pain pathology
• In early discovery, more open partnerships between
academia and industry are critical
• In vitro clinical assays are likely more predictive of activity
in patients
Chas Bountra, Chief Scientist (SGC), Professor of Translational
Medicine, University of Oxford
2.30
Highlights from AbbVie pain research: TRPV1, TrkA, Cav2.2,
and Nav1.7
• The discovery of modality specific TRPV1 antagonists that
demonstrate reduced liabilities with respect to core body
temperature increase and the loss of sensation of noxious
heat
• The discovery of Cav2.2 and Nav1.7 clinical candidates
for the treatment of chronic pain
• The discovery of TrkA inhibitors for the treatment of chronic
pain
Philip R Kym, Director of Chemistry, Centralised Lead
Optimisation, AbbVie
3.10
Afternoon Tea
ASSESSING NEW MECHANISMS - BENCH TO BEDSIDE
PART
ONE
9.10
9.50
10.30
11.00
OPENING ADDRESS
Accelerating innovation in research to build
the pain pipeline
• Filling the pain clinical development pipeline
• Open innovation in pain research
• Novel targets/mechanisms and new directions in pain
research
Samer Eid, Director, Neuroscience Scientific Knowledge
Discovery, Merck
How can in silico approaches be used to prospectively drive
membrane protein drug discovery programs?
• Importance of establishing expectations and aligning
resources accordingly
• Examples of effective applications of computational
approaches for driving drug design cycles
• Potential pit falls and future prospects
Zara Sands, Principal Scientist, Computational Medicinal
Chemist, UCB
Morning Coffee
ENHANCING THE TRANSLATION OF ANIMAL DATA INTO PAIN PATIENTS
KEYNOTE PRESENTATION
Mechanistic studies supporting the angiotensin II type
2 receptor antagonist MOA in chronic pain through to
presentation of Phase 2 efficacy and safety data
• Efficacy and safety data from Phase 2 clinical trial of EMA401
in postherpetic neuralgia.
• Mechanism of action studies in human sensory neurons and
clinical tissues.
• Update on ongoing clinical trials of EMA401.
Tom McCarthy, CEO, Spinifex
Praveen Anand, Professor of Clinical Neurology, Lead Clinician
for Pain Services, Imperial College Healthcare NHS Trust
3.40
The translational gap and assessing failures case study 1:
pre-clinical perspective
• Experimental models versus clinical trials
• Translation from animal models to man
• Failed pain mechanisms?
Professor Odd-Geir Berge, Independent Consultant,
OGBConsulting
4.20
The translational gap and assessing failures case study 2:
clinical perspective
• Translation from a clinical perspective
• Human proof of concept
• Failed mechanisms or failed studies?
Jarkko Kalliomaki, MD, PhD, Clinical Pain Research, Dept of
Molecular Medicine and Surgery, Karolinska Institutet
5.00
Chairman's Closing Remarks and Close of Day One
Q&A Session
12.20
Round Table Discussion:
Should animal models only be used for PK/PD
testing for exposure of the compound?
ROUND
TABLE
DISCUSSION
Register online at: www.pain-therapeutics.co.uk • Alternatively fax
Who should attend:
Heads of Department, Directors, Managers,
Team Leaders Researchers and Scientists from:
• Clinical Trials
• Neuroscience
• Translational Medicine/R&D
• Pain and inflammation target discovery
• Analgesic preclinical development
• CNS clinical trials
• Translational imaging
• Early phase CNS research
• Epigenetics in pain and inflammation
• Chronic and neuropathic pain
• Clinical trial design
• Pain Management
SPONSORSHIP AND EXHIBITION
OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising
and branding packages, uniquely tailored to
complement your company’s marketing
strategy. Prime networking opportunities exist
to entertain, enhance and expand your client
base within the context of an independent
discussion specific to your industry.
Should you wish to join the increasing number
of companies benefiting from sponsoring our
conferences please call:
Alia Malick on +44 (0) 20 7827 6168
or email: amalick@smi-online.co.uk
Want to know how you can
get involved?
Interested in promoting your
services to this market?
Contact Teri Arri, SMi Marketing on
+44 (0) 207 827 6162, or email:
tarri@smionline.co.uk
3. apeutics.co.uk
8.30
Registration & Coffee
9.00
Chairman's Opening Remarks
Jordi Serra, Chief Scientific Officer, Neuroscience
Technologies Ltd
Day Two | Tuesday 20th May 2014
ASSESSING NEW MECHANISMS - BENCH TO BEDSIDE
PART
1.20
New Tools in the Translation from Bench to Clinic
TWO
• Failure of recent developmental compounds
to demonstrate analgesic efficacy in the clinic
• Possible explanations based on divergent pharmacology
• New tools and approaches to better predict human
pharmacology and efficacy
Birgit Priest, Research Advisor, Eli Lilly
2.00
Overview of Fulranumab Clinical Development
• Nerve Growth factor (NGF) is elevated in tissues in
response to injury and inflammation
• Antibody inhibitors of NGF have shown efficacy in treating
pain
• Fulranumab is a fully human monoclonal antibody inhibitor
of NGF in development
• Phase 2 efficacy and safety data for fulranumab will be
presented
Dr Kathleen Kelly, Medical Leader, Janssen Pharmaceutical
Research & Development L.L.C.
2.40
Afternoon Tea
ADVANCES IN OPIOIDS
9.10
9.50
Opioids and the treatment of Chronic Pain
• The old and the new formulation of OxyContin – what is it
all about or what is the difference?
• Reviewing novel formulation strategies to reduce opioid
abuse
• Analysing the recent advances to opioids – moving
forward
Alexander Oksche, Executive Director of Pharmacological
Intelligence, Mundipharma Research
SPOTLIGHT PRESENTATION
Novel Opioid Therapeutics with Intrinsically Reduced Abuse
Potential
• NKTR-181, a slow brain entry opioid for Chronic Pain
• Opioid therapeutics with novel pharmacology for the
treatment of acute pain
Steve Harrison, Vice President, Research Biology, Nektar
Pharmaceuticals
10.30
Morning Coffee
11.00
Zero Tolerance for Chronic Pain Growth factor signaling
selectively mediates tolerance to morphine
• Growth factor inhibition eliminates or reverses morphine
tolerance.
• Newly discovered relationships between opioid tolerance
and neuropathic pain suggests that this class of drugs
could become important therapeutic targets for pain
treatment.
Howard B. Gutstein, MD, Professor, Departments of
Anesthesiology and Biochemistry/Molecular Biology MD
Anderson Cancer Center, Founder, Morpheus
Pharmaceuticals
11.40
12.20
NEUROPATHIC PAIN
3.10
Microneurography as a method for recording individual
action potentials from nociceptors and its value in drug
development in neuropathic pain.
• Analysing analgesic efficacy in preclinical animal models
• Reviewing proof-of-concept studies that allow critical
testing of presumed mechanism of action
• Recording individual action potentials from single sensory
fibres, including nociceptors to detect and quantify
abnormal activity in human pain fibres
Jordi Serra, Chief Scientific Officer, Neuroscience
Technologies Ltd
3.50
Cannabinoids in neuropathic pain: What have we learnt?
• Responses to cannabinoids across different neuropathic
pain types
• The importance of non-psychoactive cannabinoids
• Cannabinoid modulation of neurotransmission vs
inflammation
Stephen Wright, R&D Director, GW Pharmaceuticals
Discussion Panel: Strategies for reduced
PANEL
abuse potential
DEBATE
• Insights into the future of opioids
• Assessing alternatives to opioid therapeutics
• Evaluating how to move forward to minimise
opioid misuse
Steve Harrison, Vice President, Research Biology, Nektar
Pharmaceuticals
Alexander Oskche, Executive Director of Pharmacological
Intelligence, Mundipharma Research
Howard B. Gutstein, MD, Professor, Departments of
Anesthesiology and Biochemistry/Molecular Biology MD
Anderson Cancer Center, Founder, Morpheus
Pharmaceuticals
4.30 Advances into new therapeutic strategies for pain reduction
• Assessing the correlation between molecular targets and
the degree of pain
• Reviewing molecule-to-man studies combining molecular
genetics, molecular biology, and biophysics
• Demonstrating the contribution of ion channels to human
pain and the importance for axonal conduction
Fiona Boissonade, Head of Neuroscience, University of
Sheffield
Networking Lunch
5.10
Chairman’s Closing Remarks and Close of Day Two
x your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Official Media Partners
Supported by
4. INTERACTIVE POST-CONFERENCE WORKSHOP
Wednesday 21st May 2014
Holiday Inn Regents Park Hotel, London, UK
8.30am - 12.30pm
A: How Can Success in
Analgesia be Improved?
Workshop Leaders:
Steve Harrison, Vice President, Research Biology,
Nektar Pharmaceuticals
Birgit Priest, Research Advisor, Eli Lilly
Overview of the workshop
Lack of efficacy is the root cause for
approximately half of failures both in Phase II and
Phase III. This workshop will focus on addressing the
issues that are arising and evaluating how to
improve clinical trial design to ensure success.
Steve will address Nektar’s approach to improving
success, improving the efficacy and safety of
drugs known to work in the clinic.
What approaches have the Industry taken to
address this?
• Linkage between target and disease
• Disconnect between animal and human data
(what models are truly translational?)
• Phenotypic vs. target-based screening
Key Benefits of Attending:
• Gain understanding on ways to address issues
arising in clinical trial design
• Learn how to identifying key challenges in
design when benchmarking
• Enhance the translational gap between animal
and human models
• Review phenotypic vs. target-based screening
Programme
8.30
Registration and Coffee
9.00
Introduction on identifying key
challenges in clinical trial design
with a real life scenario given as the
simulation exercise
10.30
Coffee Break
11.00
The group will discuss ways to address
key issues arising in clinical trial design
11.30
Assessing the translational gap between
animal and human models
12.30
Close of Workshop
About the workshop host
Steve Harrison is responsible for the
research biology activities at Nektar
Therapeutics and leads efforts that
identify potential new drugs to treat pain
and cancer. His team supports the
transition of these new agents into clinical testing.
Prior to joining Nektar, Steve was Senior Vice
President of Research at KAI Pharmaceuticals and
led the Discovery and Preclinical efforts for that
company, involving support for clinical
development of agents in pain, cardiovascular
disease and renal dysfunction.
Birgit Priest received her Ph. D. in Biochemistry &
Biophysics from Oregon State University in 1993.
Her thesis work on muscarinic receptors was
completed under the guidance of Dr. Michael
Schimerlik. She then trained in electrophysiology
as a post-doctoral fellow in the laboratories of Dr
Joseph Patlak (University of Vermont) and Dr John
Adelman (Vollum Institute). In 1998, Birgit joined
Merck Research Labs, where, for 13 years, she
worked on a number of voltage- and ligandgated ion channel programs. At the beginning of
2011, Birgit started a position with Eli Lilly where she
continues her work of ion channel drug discovery.
Her primary research interest has been in the role
of sodium channels in sensory functions.
5. INTERACTIVE POST-CONFERENCE WORKSHOP
Wednesday 21st May 2014
Holiday Inn Regents Park Hotel, London, UK
1.30pm - 5.30pm
B: Opportunities for
Collaborative Pain Projects
Workshop Leader:
Fiona Boissonade, Head of Neuroscience,
University of Sheffield
Overview of the workshop
In modern drug discovery the path from concept
to patient is more and more dependent on
collaborations (as opposed to the “old world”
where everything was done within big pharma
companies). Centres of excellence are formed in
large pharma companies that coordinate work
performed at contract research organisations
(CROs), academia and public institutions. Also,
centres dedicated to drug discovery outside of
the traditional private sector are starting to
emerge. Among the challenges: how to achieve
transparency between the partners (e.g.
academia and industry).
This workshop will enable Industry and Academia
to discuss the alliances which hold great benefit
specifically related to pain projects for novel
analgesics. Short Case studies from Pharma and
Academia will kick-off the discussion which will
lead to a stronger working approach for targeting
novel pain therapeutics.
Key Benefits of Attending
• Gain insight on how existing alliances are
making progress
• Discuss the enhancements to ensure
collaborations are successful
• Hear the latest case studies with strategies
on how to address benefits when making a
cooperation between Pharmaceutical
Companies and Academic Institutions
• Learn what companies and academics look
to achieve from these partnerships
Programme
1.30
Registration and Coffee
2.00
Reviewing existing alliances and
making progress to partnerships
2.30
Discussing how to enhance
collaborations to ensure they’re
successful
3.00
Afternoon Tea
3.30
Evaluating strategies on how to address
benefits when make a cooperation
between Pharmaceutical Companies
and Academic institutions
4.30
Learn what companies and academics
look to achieve from partnerships
5.30
Close of Workshop
About the workshop host
Fiona Boissonade is a dental surgeon and Professor
of Neuroscience at the University of Sheffield School
of Clinical Dentistry, where she leads the
Neuroscience Research Group. Her major research
interest is in the mechanisms of altered neuronal
excitability that occur under the pathological
conditions of nerve injury and inflammation, and
which contribute to the development of chronic
pain. Her work focuses on interdisciplinary studies
funded by RCUK, industry and research charities. A
significant portion of this research has been done at
the academic–industrial interface; collaborations
with GlaxoSmithKline, Pfizer, Eli Lilly and Renovo have
funded a wide range of pre-clinical translational
studies related to pain and nerve regeneration. She
also has a number of collaborations with other
academic researchers at the University of Sheffield
and other universities in the UK and overseas (eg
Leeds University, Karolinska Institute, Yale University).
6. PAIN THERAPEUTICS
Conference: Monday 19th and Tuesday 20th May 2014, Holiday Inn Regents Park Hotel, London, UK
Workshop: Wednesday 21st May 2014, London
4 WAYS TO REGISTER
www.pain-therapeutics.co.uk
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
EARLY BIRD □
DISCOUNT □
Book by 28th February to receive £300 off the conference price
Book by 31st March to receive £100 off the conference price
CONFERENCE PRICES
Unique Reference Number
Our Reference
LV P-104
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title:
Forename:
Surname:
Job Title:
I would like to attend: (Please tick as appropriate)
COMMERCIAL ORGANISATIONS
□ Conference and 2 Workshops
□ Conference and 1 workshop
□ Conference only
□ 2 Workshops only
□ 1 workshop only
□ Workshop A
□ Workshop B
Fee
£2697.00
£2098.00
£1499.00
£1198.00
£599.00
Total
+VAT
+VAT
+VAT
+VAT
+VAT
£3236.40
£2517.60
£1798.80
£1437.60
£718.80
+ VAT
£1198.80
PROMOTIONAL LITERATURE DISTRIBUTION
Department/Division:
□ Distribution of your company’s promotional
literature to all conference attendees
£999.00
Company/Organisation:
Email:
Company VAT Number:
The conference fee includes refreshments, lunch, conference papers and access
Address:
to the Document Portal containing all of the presentations.
LIVE STREAMING/ON DEMAND/ DOCUMENTATION
Town/City:
Post/Zip Code:
Country:
Direct Tel:
Direct Fax:
Unable to travel, but would like to watch the conference live, ask questions,
participate as if you were in the room.
Price
Total
□ Live Streaming
□ On demand
Mobile:
Switchboard:
Signature:
Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title:
£999.00 + VAT (UK) £1198.80
£599.00 + VAT (UK) £718.80
(available 24 hours after the event)
□ Access to the conference documentation
on the Document Portal
£499.00 + VAT
£499.00 (or only £300 if ordered with the Document Portal)
□ The Conference Presentations - paper copy
Forename:
£598.80
£499.00
Surname:
Email:
PAYMENT
Address (if different from above):
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-104 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
Town/City:
Post/Zip Code:
Country:
Direct Tel:
Direct Fax:
VENUE Holiday Inn, Regents Park, Carburton Street, London, W1W 5EE
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
Terms and Conditions of Booking
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
of event require payment on booking. Access to the Document Portal will not be given until payment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □ we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
□ UK BACS
□ Wire Transfer
□ Cheque
□ Credit Card
Sort Code 300009, Account 00936418
Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
We can only accept Sterling cheques drawn on a UK bank.
□ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
□□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Card No:
Cardholder’s Name:
Signature:
Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live
Streaming, on Demand, Document portal and literature distribution for all UK customers and
for those EU Customers not supplying a registration number for their own country here.
______________________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk